Our Technology

Serac Healthcare is focused on bringing to market a molecular imaging agent to underpin personalised medicine in the fields of endometriosis and inflammatory arthritis. Both these conditions are affected by abnormal angiogenesis (new blood vessel formation).

Molecular Imaging

Molecular Imaging and Personalised Medicine

Molecular imaging (MI) is a type of medical imaging that provides unique insights into what is happening inside the body at the cellular and molecular level helping physicians to deliver “personalised medicine” – i.e. delivering the right treatment to the right patient at the right time, leading to better outcomes, improved quality of life and reduced costs. 

Unlike other medical imaging technologies such as x-rays, computed tomography (CT), magnetic resonance (MR), and ultrasound (US) which provide structural images, MI allows physicians to see how cells, tissues, and organs are functioning and to measure chemical and biological processes without having to resort to biopsy or surgery.

MI procedures provide important information that helps drive treatment decisions in patients with a range of conditions including cancer, infections, and disorders of the gastrointestinal, musculoskeletal, and endocrine systems, kidney, heart, lung, and other organs.

Nuclear medicine (NM) is a form of MI in which images of the uptake of injected, inhaled, or swallowed targeted radioactively-labeled tracers (radiopharmaceuticals) are captured with a gamma or SPECT camera. 

Molecular Imaging

Images Courtesy of Prof C Becker, University of Oxford and Dr T Garrood, Guy's Hospital


Ground-breaking molecular imaging technology

99mTc-maraciclatide is a radio-labeled tracer containing the RGD tripeptide motif (Arg-Gly-Asp) which binds with high affinity to αvβ3 integrin1, a cell-adhesion molecule that is up-regulated on activated vascular endothelial cells, activated macrophages and osteoclasts2.

99mTc-maraciclatide uptake in the joints has been shown to be highly correlated with power Doppler ultrasound (PDUS) in an initial proof of concept study in 5 patients3 and subsequently in a study involving 50 patients4,5.

99mTc-maraciclatide planar imaging has the potential to image the whole body, highlighting total inflammatory load in the joints in a 20-minute acquisition without requiring the rheumatologist’s time.

99mTc-maraciclatide images are easy to interpret even to the untrained observer and we are exploring ways that these images might be used to inform a patient’s view of their condition and treatment.

In endometriosis, αvβ3 integrins are selectively upregulated in blood vessels during angiogenesis6. A clinical study is underway in this patient population.



Publications and abstracts published on our research include: